Weill Medical College at Cornell University, Department of Medicine, New York, NY, USA.
Anticancer Res. 2013 Aug;33(8):3241-5.
BACKGROUND/AIM: Data on the clinicopathological features and prognostic impact of c-N-Methyl-N'-nitro-N-nitroso-guanidine HOS Transforming gene (c-MET) and hepatocyte growth factor (HGF) in hepatocellular carcinoma (HCC) are inconsistent. We assessed c-MET and HGF expression in 49 patients with early-stage HCC and correlated the results with disease characteristics and survival.
Expression of c-MET and HGF mRNA in tumor (T) and non-tumor (NT) tissues was assessed. Results were correlated with patient characteristics and overall and recurrence-free survival.
Median relative tumor c-MET and HGF expressions were 3.23 (T/NT ratio 6.46) and 9.07 (T/NT ratio 0.77), respectively. c-MET and HGF were overexpressed in early-stage disease with favorable characteristics although there was no association with survival.
Contrary to other studies, in our series increased tumor c-MET and HGF expressions were associated with favorable disease attributes but not with survival. The prognostic and therapeutic applications of this knowledge to HCC are under active investigation.
背景/目的：关于 c-N-甲基-N'-硝基-N-亚硝基胍 HOS 转化基因（c-MET）和肝细胞生长因子（HGF）在肝细胞癌（HCC）中的临床病理特征和预后影响的数据不一致。我们评估了 49 例早期 HCC 患者的 c-MET 和 HGF 表达，并将结果与疾病特征和生存相关联。
评估了肿瘤（T）和非肿瘤（NT）组织中 c-MET 和 HGF mRNA 的表达。结果与患者特征以及总生存和无复发生存相关联。
中位相对肿瘤 c-MET 和 HGF 表达分别为 3.23（T/NT 比值为 6.46）和 9.07（T/NT 比值为 0.77）。尽管与生存无关，但在具有良好特征的早期疾病中，c-MET 和 HGF 过表达。
与其他研究相反，在我们的研究系列中，肿瘤 c-MET 和 HGF 的高表达与有利的疾病特征相关，但与生存无关。该知识在 HCC 中的预后和治疗应用正在积极研究中。
